FDA Panel Cancels HIV Drug Meeting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

ROCKVILLE, Md-The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.

ROCKVILLE, Md—The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content